{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:02:01Z","timestamp":1789628521467,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR24\/00033"],"award-info":[{"award-number":["JR24\/00033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10620-026-10118-1","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:45:09Z","timestamp":1785314709000},"page":"5754-5763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU"],"prefix":"10.1007","volume":"71","author":[{"given":"Cristina","family":"Polo Cuadro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gasc\u00f3n Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00edriam","family":"Ma\u00f1osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rodr\u00edguez Moranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamile","family":"Zabana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"C\u00e9spedes Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Ord\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Miranda Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garc\u00eda de la Filia Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Roig Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ruiz Cerulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Xavier","family":"Segarra Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Matallana Royo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Esther","family":"Rodr\u00edguez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mart\u00ednez de Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Mance\u00f1ido Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Madero Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Betor\u00e9 Glar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"\u00c1lvarez Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Suris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garrido Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Brunet Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Alonso Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Santos Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Vaamonde Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Almingol Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Folguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sanz Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Moralejo Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"L\u00f3pez Couceiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Tejido Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mena S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Empar","family":"Sainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Marqu\u00e8s Cam\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Ferreiro Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Patricia","family":"Ortega Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Miles","family":"Wolfe Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Borras Garriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Herreros Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Frago Larramona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ladr\u00f3n Abia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla J.","family":"Gargallo Puyuelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mench\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mesonero Gismero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Vicente Lid\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Garc\u00eda L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6883-8940","authenticated-orcid":false,"given":"Diego","family":"Casas Deza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GETECCU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"10118_CR1","doi-asserted-by":"publisher","first-page":"1403021","DOI":"10.3389\/fmolb.2024.1403021","volume":"11","author":"C Sorino","year":"2024","unstructured":"Sorino C, Iezzi S, Ciuffreda L, Falcone I. Immunotherapy in melanoma: advances, pitfalls, and future perspectives. Front Mol Biosci. 2024;11:1403021.","journal-title":"Front Mol Biosci."},{"key":"10118_CR2","doi-asserted-by":"crossref","unstructured":"Roque K, Ruiz R, Mas L, Pozza DH, Vancini M, Silva J\u00fanior JA, et al. Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices. Cancers (Basel). 2023;15(18).","DOI":"10.3390\/cancers15184547"},{"key":"10118_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.32604\/or.2024.052207","volume":"33","author":"M Santos","year":"2025","unstructured":"Santos M, Martins D, Mendes F. Immunotherapy in gastric cancer-A systematic review. Oncol Res. 2025;33:263\u2013281.","journal-title":"Oncol Res."},{"key":"10118_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113952","volume":"147","author":"G Li","year":"2025","unstructured":"Li G, Li S, Jiang Y, Chen T, An Z. Unleashing the power of immune checkpoints: a new strategy for enhancing treg cells depletion to boost antitumor immunity. Int Immunopharmacol. 2025;147:113952.","journal-title":"Int Immunopharmacol."},{"key":"10118_CR5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u20134126.","journal-title":"J Clin Oncol."},{"key":"10118_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2739\/kurumemedj.MS682006","volume":"68","author":"T Nakane","year":"2023","unstructured":"Nakane T, Mitsuyama K, Yamauchi R, Kakuma T, Torimura T. Characteristics of immune checkpoint inhibitor-induced colitis: a systematic review. Kurume Med J. 2023;68:43\u201352.","journal-title":"Kurume Med J."},{"key":"10118_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u20131238.","journal-title":"Ann Oncol."},{"key":"10118_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.gastrohep.2023.10.009","volume":"47","author":"M Riveiro-Barciela","year":"2024","unstructured":"Riveiro-Barciela M, Carballal S, D\u00edaz-Gonz\u00e1lez \u00c1, Ma\u00f1osa M, Gallego-Plazas J, Cubiella J et al. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU. Gastroenterol Hepatol. 2024;47:401\u2013432.","journal-title":"Gastroenterol Hepatol."},{"key":"10118_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/OP.20.00002","volume":"16","author":"Z Gong","year":"2020","unstructured":"Gong Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract. 2020;16:453\u2013461.","journal-title":"JCO Oncol Pract."},{"key":"10118_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5946\/ce.2024.003","volume":"57","author":"MK Kim","year":"2024","unstructured":"Kim MK, Hwang SW. Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events. Clin Endosc. 2024;57:725\u2013734.","journal-title":"Clin Endosc."},{"key":"10118_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000278","volume":"3","author":"MH Geukes Foppen","year":"2018","unstructured":"Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.","journal-title":"ESMO Open."},{"key":"10118_CR12","unstructured":"National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Retrieved from https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"10118_CR13","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. a randomized study. N Engl J Med. 1987;317:1625\u20139.","journal-title":"N Engl J Med."},{"key":"10118_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1053\/j.gastro.2013.07.024","volume":"145","author":"SP Travis","year":"2013","unstructured":"Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987\u2013995.","journal-title":"Gastroenterology."},{"key":"10118_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u2013381.","journal-title":"J Biomed Inform."},{"key":"10118_CR16","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u20131768.","journal-title":"J Clin Oncol."},{"key":"10118_CR17","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1177\/1078155220968909","volume":"27","author":"L Nice","year":"2021","unstructured":"Nice L, Bycroft R, Wu X, Rai SN, Figg L, Bhandari S et al. Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors. J Oncol Pharm Pract. 2021;27:1736\u20131742.","journal-title":"J Oncol Pharm Pract."},{"key":"10118_CR18","doi-asserted-by":"crossref","unstructured":"Favara DM, Spain L, Au L, Clark J, Daniels E, Diem S, et al. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open. 2020;5(4).","DOI":"10.1136\/esmoopen-2019-000585"},{"key":"10118_CR19","doi-asserted-by":"crossref","unstructured":"Mooradian MJ, Wang DY, Coromilas A, Lumish M, Chen T, Giobbie-Hurder A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer. 2020;8(1).","DOI":"10.1136\/jitc-2019-000451"},{"key":"10118_CR20","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3748\/wjg.v23.i11.2023","volume":"23","author":"A Jain","year":"2017","unstructured":"Jain A, Lipson EJ, Sharfman WH, Brant SR, Lazarev MG. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol. 2017;23:2023\u20132028.","journal-title":"World J Gastroenterol."},{"key":"10118_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","volume":"123","author":"VTF Cheung","year":"2020","unstructured":"Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer. 2020;123:207\u2013215.","journal-title":"Br J Cancer."},{"key":"10118_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.gie.2024.01.024","volume":"100","author":"Y Wang","year":"2024","unstructured":"Wang Y, Abu-Sbeih H, Tang T, Shatila M, Faleck D, Harris J et al. Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients. Gastrointest Endosc. 2024;100:273\u201382.e4.","journal-title":"Gastrointest Endosc."},{"key":"10118_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/ecco-jcc\/jjv047","volume":"9","author":"C Corte","year":"2015","unstructured":"Corte C, Fernandopulle N, Catuneanu AM, Burger D, Cesarini M, White L et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015;9:376\u2013381.","journal-title":"J Crohns Colitis"},{"key":"10118_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000507579","volume":"5","author":"J Burla","year":"2020","unstructured":"Burla J, Bluemel S, Biedermann L, Barysch MJ, Dummer R, Levesque MP et al. Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course. Inflamm Intest Dis 2020;5:109\u2013116.","journal-title":"Inflamm Intest Dis"},{"key":"10118_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 2018;6:142.","journal-title":"J Immunother Cancer"},{"key":"10118_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/mco.2021.2227","volume":"14","author":"Y Kadokawa","year":"2021","unstructured":"Kadokawa Y, Takagi M, Yoshida T, Tatsumi A, Fujita K, Inoue T et al. Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: a retrospective study. Mol Clin Oncol 2021;14:65.","journal-title":"Mol Clin Oncol"},{"key":"10118_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","volume":"6","author":"DH Johnson","year":"2018","unstructured":"Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018;6:103.","journal-title":"J Immunother Cancer"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10118-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:05:21Z","timestamp":1789625121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10118-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10118"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10118-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DCD has served as speaker, consultant, and advisory member or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Taked, Janssen, Ferring, Faes Farma, and Alfasigma. EBM has served as a speaker and consultant for Janssen and Chiesi, Kern, Takeda, and Alfasigma. VMR has served as a speaker or consultant for Abbvie, Allergan, Casen Recordati, Italf\u00e1rmaco S.A., Janssen Cilag S.A., Merck Sharp & Dohme Espa\u00f1ola S.A., Pfizer, Schwabe Farma Ib\u00e9rica S.A.U., and y Takeda. MBA has been a speaker, consultant, and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Alphasigma, Lilly, Pfizer, Sandoz, Biocon, Abivax, Fresenius, Faes Farma, Ferring, Tillots, Chiesi, Adacyte, SunRock, and Oncostellae. MMC has served as speaker and consultant or has received research funding form Abbvie, Janssen, GSK, and Ferring. CR has received support for conference attendance and education funding from Kern Pharma, Ferring, Alfasigma, Faes Farma, Pfizer, and Takeda. JMB has received support for conference attendance, speaker fees, and consulting and advisory fees from AbbVie, Lilly, Adacyte, Dr Falk Pharma, FAES Pharma, Ferring, Janssen, Pfizer, Takeda, and Galapagos y Tillots. YZ has received financial support for traveling and educational activities from or has served as an advisory board member for AbbVie, Adacyte, Alfasigma, Almirall, Amgen, Boehringer Ingelheim, Dr Falk Pharma, Faes Pharma, Fresenius Kabi, Ferring, Galapagos, Janssen, Johnson&Johnson, Kern, Lilly, MSD, Otsuka, Pfizer, Sanofi, Shire, Takeda, and Tillotts Pharma. IO has received financial support for traveling and educational activities from or has served as an advisory board member or speaker for Abbvie, MSD, Pfizer, Takeda, Janssen, Kern Pharma, Chiesi, Falk Pharma, and Faes Farma. Research support from Abbvie and Faes Farma.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}